Our News

Akamis Bio Receives FDA Fast Track Designation for NG-350A for the Treatment of Mismatch Repair-Proficient Locally Advanced Rectal Cancer

Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors

Akamis Bio Broadens Leadership Team with Key Executive Appointments

Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer

Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnership